Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization
NCT07187804
Age-Related Macular Degeneration (ARMD), Anti-vascular Endothelial Growth Factor
Seoul, South Korea
View Trial DetailsNCT Number: NCT06583109
Age-related macular degeneration (AMD) is one of the main causes of blindness in the elderly population. Intraocular injection of anti-VEGF drugs for neovascular AMD (nAMD) is the main treatment method at present. However, patients have different responses to anti-VEGF therapy, and some patients do not respond well to short - and long-term treatment.
In this study, a retrospective study was adopted to collate and analyze the clinical data and imaging data of nAMD in the past, and to extract the imaging features from the multimodal modalities before and after treatment for deep learning, and to evaluate and quantify the clinical features, and to construct two multi-source feature models for predicting the short-term and long-term prognosis of nAMD patients. By verifying the accuracy of the model to predict the curative effect, the classification efficiency of the above characteristic models was compared, and the optimal model was selected. Its clinical application value was evaluated by calibration curve and decision curve. In addition, patients with poor treatment response in the study cohort were retrospectively analyzed, and the efficacy and safety of the combination of other treatment options in the actual clinic were analyzed. The purpose of this study is to provide scientific basis for early prediction, dynamic monitoring and optimization of overall treatment strategies for nAMD.
Trial opening soon.
Get Notified50 year and older
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline, 3 months after anti-VEGF treatment, 1 year after anti-VEGF treatment
best-corrected visual acuity using LogMAR
Time frame: Baseline, 3 months after anti-VEGF treatment, 1 year after anti-VEGF treatment
central macular thickness measured on OCT
Contact information is provided by the study sponsor or research team.
Beijing Hospital
Other Gov
Establishment and Application of Prediction Model of Treatment Efficacy for Age-related Macular Degeneration Based on Multi-source Imaging Modalities
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07187804
Age-Related Macular Degeneration (ARMD), Anti-vascular Endothelial Growth Factor
Seoul, South Korea
View Trial DetailsNCT06662162
Age-Related Macular Degeneration, Age-Related Macular Degeneration (ARMD)
Manchester, Connecticut, United States
View Trial DetailsNCT06683950
Age-Related Macular Degeneration (ARMD), Choroid Diseases
Seoul, South Korea
View Trial DetailsNCT05735730
Age-Related Macular Degeneration (ARMD), Eye Diseases
Coimbra, Portugal
View Trial Details